AXSM News and Press, Axsome Therapeutics Inc. From 12/10/22

Momentum: In physics, it's a measure of mass and velocity. For stocks, it's the velocity of price changes. But in both realms, momentum can be sustained or it can be lost. Investors obviously prefer stocks with momentum that can keep it going. With this in mind, we asked three Motley Fool con...

This year hasn't been the easiest for investors. The three major indexes headed into bear territory. Many of even the strongest stocks suffered. And as a result, investors' portfolios suffered, too. But there's reason to be positive as we exit this year and enter a new one. First of all, bear...

Summary In its early launch for depression, Axsome Therapeutics, Inc.'s Auvelity is already garnering robust market adoption. Demonstrating its therapeutic prowess, Auvelity also recently reported superb data for the Phase 3 ACCORD trial for Alzheimer's disease agitation. Going into...

This year has been one of losses for many top stocks. Higher inflation and a generally pessimistic market sentiment have weighed on market performance across industries. But some companies have managed to defy this negative trend -- and beat the bear market. Two biotech companies are great ex...

Axsome Therapeutics ( NASDAQ: AXSM ) said it medicine Auvelity showed substantial and durable improvements in cognitive and physical functioning in patients with major depressive disorder (MDD) in the open-label trial EVOLVE. Auvelity is approved to treat MDD in adults. I...

Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting at week 1 and sustained over 12 months NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ax...

It takes money to make... wait, you've heard this before, right? Everyone knows that money doesn't materialize out of thin air. You have to start off with some amount up front. And you need a great way to put that initial money to work for you. The good news is that there are lots of stocks y...

With shares of Axsome Therapeutics (NASDAQ: AXSM) skyrocketing 87% so far this year, the biotech's shareholders are doubtlessly pleased. Thanks to a pair of newly approved products, growth is finally on the way -- with revenue set to go from practically $0 to more than $100 million in the...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Khairil Azhar Junos/Shutterstock.com Recent reports claim that Tesla (NASDAQ: TSLA ) is planning to revamp the Model 3 under the secret “Highland” project. The Tesla Model 3 was first int...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Stock-Asso / Shutterstock.com Swvl (NASDAQ: SWVL ) layoffs are here again as the micro-mobility company seeks to reduce costs by cutting more than 50% of its workforce. According to Swvl, these lates...